Highlights

  • Aroa Biosurgery reported FY26 Revenue of NZ$103.9 million, up 23%, exceeding guidance expectations on constant currency terms.
  • Normalised EBITDA improved significantly to NZ$12.6 million compared to NZ$4.2 million in FY25, reflecting Operating Leverage and improved scale.
  • The company generated positive Operating Cash Flow of NZ$10.5 million and ended the year with NZ$27.1 million in cash and no Debt.

 

Aroa Biosurgery Limited (ASX:ARX) traded at A$0.63, rising 1.61% on the day of its FY26 results release. Over the past year, the stock has increased approximately 36.96%, reflecting improving financial performance and sustained revenue growth momentum across its surgical reconstruction product portfolio.

The market reaction to the FY26 results was measured, with attention focused on continued revenue expansion, Margin stability, and the transition toward more consistent Earnings generation. The share price movement reflects incremental re-rating dynamics rather than a single-step repricing event, consistent with the company’s gradual improvement in operating fundamentals.

FY26 Revenue Performance and Product Mix Expansion

Aroa Biosurgery reported total revenue of NZ$103.9 million for FY26, representing 23% growth compared to the prior financial year. On a constant currency basis, revenue reached NZ$101.3 million, exceeding the company’s previously guided range of NZ$92–100 million.

Growth was primarily driven by the Myriad™ product line, which generated NZ$49.5 million in revenue, increasing 54% year-on-year. This segment continues to serve as the primary growth engine within Aroa’s portfolio, supported by expanding clinical adoption and increased penetration within US surgical applications.

The OviTex™ and OviTex™ PRS product range contributed NZ$42.8 million in revenue, reflecting 8% growth. While still a meaningful contributor to total revenue, growth in this segment was comparatively more moderate, influenced by product mix dynamics and channel distribution changes.

The direct sales channel accounted for 59% of total product revenue and remained the fastest-growing distribution pathway, indicating continued strategic emphasis on higher-margin direct customer relationships.

Margin Stability and Cost Structure Dynamics

Aroa maintained a product gross margin of 85.5%, broadly consistent with the prior year. This stability reflects offsetting factors within the cost structure, including higher indirect Manufacturing expenses and a shift in product mix away from higher-margin legacy volumes.

Operating expenses increased during FY26, with selling and administrative costs rising 15% to NZ$74.6 million. The increase was primarily driven by expanded sales activity, higher variable compensation linked to performance outcomes, and increased Investment in clinical development initiatives.

Research and Development expenses declined to NZ$7.9 million from NZ$9.6 million in FY25. The reduction was largely timing-related, reflecting lower-than-expected spend on joint development projects and clinical study activities. Despite the reduction, ongoing R&D remains focused on product extensions and pipeline development, including the Myriad MASTRR registry and Symphony clinical program.

The overall cost structure reflects a transition phase in which revenue scale is increasing faster than Fixed Cost growth, supporting improved operating leverage.

EBITDA Expansion and Operating Performance Shift

Aroa reported normalised EBITDA of NZ$12.6 million in FY26, a significant increase from NZ$4.2 million in FY25. On a constant currency basis, EBITDA reached NZ$11.3 million, exceeding the company’s guidance range.

The improvement reflects a combination of revenue growth, stable gross margins, and controlled overhead expansion relative to scale. While operating expenses increased in absolute terms, revenue growth outpaced cost expansion, resulting in improved earnings conversion.

The EBITDA performance also reflects stronger contribution from Myriad sales, which continue to demonstrate higher scalability within the company’s commercial model. However, management has indicated that FY27 will involve deliberate reinvestment in commercial infrastructure, which is expected to moderate near-term EBITDA expansion.

Cash Flow Performance and Balance Sheet Position

Aroa generated NZ$10.5 million in operating cash inflows during FY26, marking a notable improvement from an outflow of NZ$2.6 million in the prior year. The improvement was supported by higher earnings and improved receivables collection efficiency.

Investing cash outflows remained relatively stable at NZ$3.7 million, with a shift in composition between Capital Expenditure and capitalised development costs. Capital expenditure declined, while development-related investment increased modestly, reflecting ongoing product and clinical program support.

The company ended FY26 with NZ$27.1 million in cash and term deposits and no debt. Total net cash flow for the year was positive at NZ$5.1 million, reinforcing its position as a self-funded growth Business.

This balance sheet profile provides flexibility for continued investment in commercial expansion without immediate reliance on external funding.

FY27 Outlook: Growth and Investment Balance

Aroa has guided FY27 revenue to NZ$115–125 million, representing constant currency growth of 13–23%. Within this, direct sales are expected to grow between 24% and 40%, driven by continued expansion of the Myriad Franchise and early contribution from Symphony.

Sales to TELA Bio are expected to remain flat, indicating a greater reliance on direct channel expansion rather than distributor-led growth.

Normalised EBITDA guidance for FY27 is NZ$8–11 million, reflecting a temporary moderation compared to FY26. This is primarily due to planned investment of approximately NZ$9 million in commercial Leadership, salesforce expansion, and operational infrastructure.

Management has framed this investment phase as a strategic allocation toward capturing Market Share in a shifting competitive environment, particularly within the skin substitute and reconstructive surgery markets. The launch and scaling of Symphony is positioned as a potential medium-term growth driver, although near-term financial impact is expected to be investment-weighted.

Strategic Positioning and Product Pipeline Development

Aroa Biosurgery operates within the regenerative tissue repair and surgical reconstruction segment, with a product portfolio focused on biologic-derived soft tissue repair solutions.

The Myriad product suite continues to represent the core growth driver, supported by increasing adoption in complex surgical procedures. Meanwhile, OviTex products provide Diversification across surgical applications and distribution channels.

The company’s clinical development pipeline, including Symphony and Enivo, is aimed at expanding addressable markets and strengthening long-term competitive positioning. These initiatives remain in development and will require ongoing investment before reaching meaningful commercial scale.

Conclusion

Aroa Biosurgery’s FY26 results reflect continued revenue expansion, improving earnings quality, and a strengthening cash flow profile. The company has demonstrated meaningful operating leverage through its Myriad franchise while maintaining stable margins and a strong balance sheet. FY27 guidance indicates a strategic shift toward reinvestment in commercial capabilities and pipeline expansion, positioning the business for longer-term growth while moderating near-term EBITDA progression. The overall financial trajectory suggests a company transitioning from early growth acceleration into a phase focused on scaling commercial infrastructure and broadening product adoption.